Cisplatin
Manufacturing · 1-10 Employees
View Company Info for Free
Overview
Phone Number
(512) 436-0574Website
www.cisplatin.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cisplatin
Bristol-Myers Squibb is a pharmaceutical company that markets Cisplatin, a widely used chemotherapy drug for treating various cancers including sarcoma, lung cancer, and ovarian cancer. Cisplatin is recognized for its effectiveness as an alkylating agent, technically classified as a platinum-based drug that has played a significant role in cancer treatment since the 1970s. The drug is utilized in combination with other treatments, maintaining its relevance in modern oncology despite the introduction of newer therapies. The company, along with others, produces and distributes this generic medication, emphasizing its importance in cancer care.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cisplatin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cisplatin had a recent Job posting/layoffs
Check if Cisplatin has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cisplatin
Funding: Get notified immidiatlly once Cisplatin has new funding data
Product Launch: Get notified when Cisplatin launches new products
Website visits: Recent activity has been detected on your website
Cisplatin, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Cisplatin is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cisplatin recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cisplatin
Compare insights from companies similar to Cisplatin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cisplatin
<$5M
1-10
Private
-
2007
N/A
Company Profile Activity
Activity Insights
Cisplatin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cisplatin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cisplatin.
Cisplatin Tech Stack
A closer look at the technologies used by Cisplatin
Cisplatin News & Media
OV - Oncology Venture receives authority clearance to expand an ongoing Phase 2 study of LiPlaCis by inclusion of prostate cancer patients
Hoersholm, Denmark, October 4, 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) announces that the Danish Medicines Agency (DKMA) has approved an application to broaden the scope of an ongoing Phase 2 study of LiPlaCis ® - an intelligent, target controlled liposome formulation of one of the world's most widely used chemotherapies, cisplatin. The authority clearance will allow inclusion of prostate cancer patients into the clinical study, which has so far been focusedOV - Updated LiPlaCis data positions LiPlaCis and its DRP for an FDA Breakthrough Therapy designation application for breast cancer
Hoersholm, Denmark, September 17, 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or "the Company") announce the fourth update from the ongoing LiPlaCis ® Phase 2 study. In the ongoing study, the data points to the possibility of obtaining a Breakthrough Therapy designation by the FDA. In the LiPlaCis DRP top tier group (1/3) of highest likelihood responders (nine of 18 patients) five (55%) obtained a partial remission*. A response rate ofStrong LiPlaCis Treatment Results in DRP-Selected Breast Cancer Patients Collaborative LiPlaCis Regulatory Meeting with DKMA
Oncology Venture Provides Clinical and Business Update Hoersholm, Denmark, 02 July 2018 – Oncology Venture Sweden AB (SPOTLIGTH: OV.ST) (“OV” or “the Company”) and MPI announce the third interim report from the ongoing LiPlaCis® Phase 2 study in hard-to-treat metastatic breast cancer patients and outcomes of a recent meeting with the Danish Medicines Agency (DKMA). Regulatory: In this constructive meeting, the Company discussed the interim Phase 2 LiPlaCis data with the DKMA along with a
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cisplatin
Sign Up For FreeTo access detailed company insights
Bristol-Myers Squibb is a pharmaceutical company that markets Cisplatin, a widely used chemotherapy drug for treating various cancers including sarcoma, lung cancer, and ovarian cancer. Cisplatin is recognized for its effectiveness as an alkylating agent, technically classified as a platinum-based drug that has played a significant role in cancer t... Read More
